AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05811260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post facilitation stretch .
Description: static stretching exercises for the low back (plantar fascia, gastrocnemius, hamstrings, and erector spinae). Static stretching involved 3 sets of 3 repetitions for each muscle with a 30-second hold and 30-second rest interval for each repetition.
Study NCT05558852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Meshless Sacrocolpopexy Technique
Description: Meshless sacrocolpopexy: laparoscopic approach to central and anterior compartment prolapse
Study NCT05563584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Rehab
Description: A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
Study NCT06516393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The radial shock wave device
Description: The r-ESWT+Kinesio Tape Application
Study NCT06516393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The radial shock wave device
Description: The r-ESWT+Kinesio Tape Application
Study NCT04172779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Oral administration of erlotinib 25mg tablet
Study NCT04638725 — intervention group
Intervention type: OTHER
Intervention: Blood sample for genetic analysis
Description: Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
Study NCT05068180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose neuroleptanalgesia
Description: Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
Study NCT05068180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
Study NCT05584618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: education
Study NCT05915247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HER-096
Description: Administered as a single dose via s.c. injection
Study NCT05915247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single dose via s.c. injection
Study NCT04814381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + Magnesium sulfate (drug combination)
Description: A single infusion will be performed over 2 hours with 90 days follow-up.
Study NCT04814381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + Magnesium sulfate (drug combination)
Description: A single infusion will be performed over 2 hours with 90 days follow-up.
Study NCT05003167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST-150)
Description: All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).
Study NCT04987307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavaleukin alfa
Description: Efavaleukin alfa will be administered by subcutaneous (SC) injection.
Study NCT04987307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection.
Study NCT04735510 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine ophthalmic emulsion 0.05%
Description: All subjects will receive restasis
Study NCT05517863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before
Study NCT05517863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy
Description: All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before
Study NCT05598463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OASIS Pro
Description: This device can track the joint movement and provide real-time feedback on the exercise performance and accuracy using Kinect camera sensor, and Wearable sensor (IMU). This device is connected to the website, which available for medical staff prescribe the exercise protocol and monitor individual exercise adherence.
Study NCT04580524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair of ventral hernia using biologic mesh
Description: Ventral hernia will be repaired using biologic mesh
Study NCT04580524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair of ventral hernia using suture repair or synthetic mesh
Description: Ventral hernia will be repaired using the current treatment methods
Study NCT05264766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling helmet on
Description: Cooling helmet with circulating cold water
Study NCT05264766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooling helmet off
Description: Cooling helmet without circulating cold water
Study NCT05765045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nursing triage protocol
Description: Medically approved and supervised standing order that allows trained ER nurses to start medical imaging (RX) for adult patients with minor traumata to the limbs.
Study NCT04765189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.
Study NCT04765189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum A
Description: Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.
Study NCT04329104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-MALMAB0100-00-AB (CIS43LS)
Description: Administered via one-time IV infusion
Study NCT04329104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Administered via one-time IV infusion
Study NCT06072352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal cleansing using chlorhexidine acetate solution
Description: Perineal cleansing using chlorhexidine acetate solution
Study NCT06072352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Perineal cleansing using normal saline
Study NCT04765189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum B
Description: Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.
Study NCT04765189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum C
Description: Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.
Study NCT06680089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RCCB6
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
Study NCT05510102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WHOOP strap 4.0 (full data access)
Description: The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
Study NCT06692166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: 1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
Study NCT06692166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days
Study NCT06697977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytosterols
Description: 2 grams of phytosterols given as 7 pills per day
Study NCT05510102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WHOOP strap 4.0 (partial data access)
Description: The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
Study NCT06697977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 7 pills per day
Study NCT06701227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In Situ Simulation
Description: The simulation scenario included briefing (5 min), scenario (10 min), and debriefing (20 min).~Materials and Simulators: neonatal mannequin, with its crying controlled by a smartphone; breastfeeding simulator that had the function of ejecting liquid imitating human milk.~Team: One facilitator and one actor playing a Community Health Worker.
Study NCT06703411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose IV
Description: IV iron sucrose 200mg per visit
Study NCT06703411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard of care (HFrEF 4 pillars treatment)
Study NCT06703411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard of care (HFrEF 4 pillars treatment)
Study NCT06704113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meloxicam 7,5mg
Description: Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen
Study NCT06703905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded pancreaticoduodenectomy surgery
Description: Traditional minimally invasive pancreaticoduodenectomy combined with the TRIANGLE procedure
Study NCT06703905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Description: Traditional minimally invasive pancreaticoduodenectomy
Study NCT06195267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat
Description: The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.
Study NCT06195267 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Blank control
Description: Patients only received standard treatment and care.
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102 subcutaneous (SC)
Description: 0.12 mg/kg, 0.24 mg/kg or Recommended phase 2 dose of GI-102 will be administered via SC injection Q3W up to 2 years (approximately 35 years).
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102
Description: Dose level will be escalated from 0.06 mg/kg to 0.45 mg/kg and Recommended phase 2 dose (or RP2D-1, RP2D+1) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin will be administered intravenously at a dose of 75 mg/m2 on Day 3 every 3-week (21-day) cycle for up to 6 cycles.
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered intravenously over 1 hour at a dose of 80 mg/m2 each time weekly as a diluted solution according to the prescribing information.
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin
Description: Eribulin will be administered intravenously at a dose of over 1.4 mg/m2 over 2 to 5 minutes on Days 3 and 10 every 3-week (21-day) cycle.
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan (T-DXd)
Description: T-DXd will be administered initially as a 5.4 mg/kg (or 6.4 mg/kg only for gastric cancer) IV over 30 - 90 minutes every 3 weeks.
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
Study NCT05824975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-102
Description: Recommended phase 2 dose (or RP2D-1, RP2D-2) of GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Study NCT06122571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConcenTrace
Description: The product contains concentrated seawater from Utah's inland sea.
Study NCT05941299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REGENERA breast implant implantation
Description: Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:~* Screening~* Pre-surgery treatment~* Surgery and study device implant~* Post-surgery follow-up
Study NCT03716999 — intervention group
Intervention type: OTHER
Intervention: Starlight Therapy
Description: Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
Study NCT06374121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerSorb cartridge (CytoSorbents Europe GmbH, Germany)
Description: This is a highly bio-/hemo-compatible, low-flow resistance polymer cartridge able to remove cytokines and other inflammatory mediators via adsorption.
Study NCT06374121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PerLife PerKidney
Description: The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.
Study NCT06374121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerLife PerKidney
Description: The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.
Study NCT05947448 — intervention group
Intervention type: DRUG
Intervention: Azilsartan Medoxomil Potassium Tablet
Description: Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month
Study NCT06401642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: 10 mg intranasal
Study NCT04767022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB)
Description: Drug Coated Balloon
Study NCT04767022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)
Description: Drug Coated Balloon
Study NCT05617625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant
Study NCT05617625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant
Study NCT05617625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant
Study NCT05617625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)
Description: CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.
Study NCT05202600 — intervention group
Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical removal of the vermiform appendix.
Study NCT05947448 — intervention group
Intervention type: DRUG
Intervention: Nifedipine Sustained -release Tablets
Description: Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；
Study NCT05947448 — intervention group
Intervention type: DRUG
Intervention: Levoamlodipine Maleate Table
Description: Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；
Study NCT06077006 — intervention group
Intervention type: OTHER
Intervention: questionnaires Only
Description: questionnaires Only
Study NCT05466318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg oral twice weekly for 2 weeks
Study NCT05466318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 6 mg/m2 intravenously once daily @ Day -7 \~ -3
Study NCT05466318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2500 mg/m2 intravenously @ Day -7, -3
Study NCT05466318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg intravenously once daily @ Day -7 \~ -4
Study NCT05466318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: 300 mg/m2 intravenously @ Day -8
Study NCT05466318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 200 mg/m2 intravenously once daily @ Day -7 \~ -4
Study NCT05466318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 400 mg/m2 intravenously once daily @ Day -7 \~ -4
Study NCT05466318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 140 mg/m2 intravenously @ Day -3
Study NCT05466318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous hematopoietic stem cell transplant
Description: autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
Study NCT05466318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant
Description: autologous hematopoietic stem cells infusion after ChiCGB or BEAM chemotherapy
Study NCT06524050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care
Description: standard care
Study NCT04905901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid nebulization 15 minutes before sinus surgery
Study NCT05493605 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope
Description: The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
Study NCT06352034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathy Training
Description: The intervention contains five themes: 1) An overview of empathy and emotions. 2) Cognitive empathy and clarification technique. 3) Emotional empathy and reflection of feelings technique. 4) Awaring and dealing with the inner feelings while empathizing. 5) Empathy timing and emotional pendulum technique.
Study NCT05401669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-radial access
Description: Cerebral angiography performed by trans-radial access
Study NCT05401669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-femoral access
Description: Cerebral angiography performed by trans-femoral access
Study NCT04586023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenebrutinib
Description: Participants will receive fenebrutinib.
Study NCT04586023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Participants will receive teriflunomide.
Study NCT04586023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
Study NCT04586023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.